Pancreatic cancer – cost for overtreatment with gemcitabine

References

• Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54: 385–7.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607–20.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Sun C, Ansari D, Andersson R, Wu D. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? A meta-analysis of 26 randomized controlled clinical trials. World J Gastroenterol 2012;18: 4944–58.
   PubMed Web of Science ®Google Scholar
• Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, et al. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: Identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol Membr Biol 2001;18:65–72.
   PubMed Web of Science ®Google Scholar
• Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2’,2’-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 2003;9: 5000–8.
   PubMed Web of Science ®Google Scholar
• Spratlin JMJ. Human Equilibrative Nucleoside Transporter 1 (hENT1) in pancreatic adenocarcinoma: Towards individualized treatment decisions. Cancers 2010;2:11.
   Google Scholar
• Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008;299:1019–26.
   PubMed Web of Science ®Google Scholar
• Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187–95.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006;66: 3928–35.
   PubMed Web of Science ®Google Scholar
• Marechal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 2009;15:2913–9.
   PubMed Web of Science ®Google Scholar
• Morinaga S, Nakamura Y, Watanabe T, Mikayama H, Tamagawa H, Yamamoto N, et al. Immunohistochemical analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol 2012;19(Suppl 3):S558–64.
   Web of Science ®Google Scholar
• Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004;10:6956–61.
   PubMed Web of Science ®Google Scholar
• Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W, et al. Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scand J Gastroenterol 2009;44:782–6.
   PubMed Web of Science ®Google Scholar
• Bergman AM, Pinedo HM, Peters GJ. Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002;5:19–33.
   PubMed Web of Science ®Google Scholar
• Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005;65:9510–6.
   PubMed Web of Science ®Google Scholar
• Kroep JR, Loves WJ, van der Wilt CL, Alvarez E, Talianidis I, Boven E, et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 2002;1:371–6.
   PubMed Web of Science ®Google Scholar
• Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110–8.
   PubMed Web of Science ®Google Scholar
• Boeck S, Raponi M, Richardson B, Towne P, Isaacson J, Ranger Moore J, et al. Development of the SP120 rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma. J Clin Oncol 2012;30(Suppl):abstr 4041.
   Google Scholar
• Raponi M, Boeck S, Richardson B, Towne P, Isaacson J, Ranger-Moore J, et al. Two-thirds of pancreatic ductal adenocarcinomas have low expression of hENT1 as determined by the SP120 rabbit monoclonal antibody immunohistochemistry test. World GI 2012 (abstract).
   Google Scholar
• Bra att veta om sjuklön. National Social Insurance Office, Sweden. Faktablad. [cited 2012 Feb 28]. Available from: http://www.forsakringskassan.se
   Google Scholar
• Tingstedt B, Isaksson J, Andersson R. Long-term follow-up and cost analysis following surgery for small bowel obstruction caused by intra-abdominal adhesions. Br J Surg. 2007;94:743–8.
   PubMed Web of Science ®Google Scholar
• Södra regionsvårdsnämnden. Regionala priser och ersättningar för södra sjukvårdsregionen 2011. [cited 2012 Mar 6]. Available from http://www.skane.se/sv/Webbplatser/Sodra-regionvardsnamnden/
   Google Scholar
• Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004;22:854–63.
   PubMed Web of Science ®Google Scholar
• Tingstedt B, Andersson E, Flink A, Bolin K, Lindgren B, Andersson R. Pancreatic cancer, healthcare cost, and loss of productivity: A register-based approach. World J Surg 2011; 35:2298–305.
   PubMed Web of Science ®Google Scholar
• Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG9704. Pharmacogenomics J2012;12: 395–403.
   Google Scholar
• Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010;16:320–9.
   PubMed Web of Science ®Google Scholar